Tahseen I. Al-Saleem, MD

Tahseen Al-Saleem, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111


Research Program

Treatment Philosophy

I chose to work at Fox Chase because I like oncologic (cancer) pathology and love the institutional environment. The best part of my job is interaction with other colleagues: pathologists, clinicians and researchers. That is why I've stayed at Fox Chase for more than 15 years.

Advances in medicine have improved the way in which we understand cancer and deal with it. An accurate, comprehensive diagnosis means everything to the patients who come here as well as the physicians who plan their treatment. As a pathologist, I enjoy working with the other physicians because they count on our accuracy in order to get best results in cancer management and for future progress in the field.

Education, Training & Credentials

Educational Background

    St. Christopher's Hospital for Children, Philadelphia - See more at:
    • Fellow, St. Christopher's Hospital for Children, Philadelphia, PA
    • Resident, Pathology, Temple University Hospital, Philadelphia, PA
    • Board Member, Hematology, University of Baghdad School of Medicine, Iraq, 1999
    • AP/CP, Pathology, University of Baghdad School of Medicine, Iraq, 1970
    • MB, ChB, Medicine, University of Baghdad School of Medicine, Iraq, 1961


    • American Board of Pathology
    • Anatomic and Clinical Pathology
    • Hematopathology


    • College of American Pathologists
    • Clinical Cytometry Society
    • American Society of Hematology

    Honors & Awards

    • Lifetime Achievement Award, Iraqi Society of United Kingdom, 2016
    • Best Medical Oncology Teacher, Fox Chase Cancer Center, 2005
    • Best Professor's Award, University of Baghdad, 1985
    Research Profile

    Research Program

    Research Interests

    • Contribution to the development of animal models for lymphoma
    • Investigation and description of new or unusual hemopoietic malignancies

    Selected Publications

    Reyes VE Jr, Al-Saleem T, Robu VG, Smith MR. Extranodal NK/T-cell lymphoma nasal type: Efficacy of pegaspargase. Report of two patients from United States and review of literature. Leuk Res. 2010 Jan;34(1):e50-4. Epub 2009 Sep 27. PubMed

    Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM. The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92002. Clin Cancer Res. 2009 Sep 1;15(17):5478-84. Epub 2009 Aug 25. PubMed

    Kadariya Y, Yin B, Tang B, Shinton SA, Quinlivan EP, Hua X, Klein-Szanto A, Al-Saleem TI, Bassing CH, Hardy RR, Kruger WD. Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res. 2009 Jul 15;69(14):5961-9. Epub 2009 Jun 30. PubMed

    Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer; RTOG 92-02. J Clin Oncol. 2009 Jul 1;27(19):3177-84. Epub 2009 May 26. PubMed

    Gitelson E, Al-Saleem T, Smith MR. Lymphomatoid granulomatosis; challenges in diagnosis and treatment. Clin Adv Hematol Oncol. 2009 Jan;7(1):68-70. PubMed

    Shafer D, Wu H, Al-Saleem T, Reddy K, Borghaei H, Lessin S, Smith M. Cutaneous precursor B-Cell lymphoblastic lymphoma in2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature. Arch Dermatol. 2008 Sep;144(9):1155-62. PubMed

    Jambusaria A, Shafer D, Wu H, Al-Saleem T, Perlis C. Cutaneous plasmablastic lymphoma. J Am Acad Dermatol. 2008 Apr;58(4):676-8. PubMed

    Rothman J, Crispen PL, Wong YN, Al-Saleem T, Fox E, Uzzo RG. Pathologic concordance of sporadic synchronous bilateral renal masses. Urology. 2008 Jul;72(1):138-42. Epub 2008 Mar 12. PubMed

    Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res. 2008 Feb 15;68(4):998-1002. PubMed

    D'Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1082-7. Epub 2007 Jan 22. PubMed

    Narra K, Borghaei H, Al-Saleem T, Höglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leuk Res. 2006 Jan;30(1):109-14. Epub 2005 Jul 25. PubMed

    Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk Lymphoma. 2006 Sep;47(9):1902-7. PubMed

    Al-Saleem T, Balsara BR, Liu Z, Feder M, Testa JR, Wu H, Greenberg RE. Renal oncocytoma with loss of chromosomes Y and 1 evolving to papillary carcinoma in connection with gain of chromosome 7. Coincidence or progression? Cancer Genet Cytogenet. 2005 Nov;163(1):81-5. PubMed

    Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (PSID): a model for mature B-cell neoplasms. Blood. 2005 Mar 15;105(6):2274-80. Epub 2004 Nov 12. PubMed

    Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9. PubMed